Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on February 5, 2018 (with events reported through February 8, 2018). The filing details a strategic pivot in the company's development of its drug candidate RX-0201 (Archexin), an Akt-1 inhibitor for cancer treatment. The company terminated a long-standing collaboration with a Korean partner to enter a new agreement with a Chinese partner focused on hepatic cell carcinoma (HCC).
Key Financial Metrics and Agreements
This filing does not contain standard financial statements (revenue, profit, cash flow, or debt). However, it outlines specific financial terms of new and terminated agreements:
- Termination Payout Cap: Rexahn agreed to pay its former partner (NEXT BT) royalties and a percentage of future payments, capped at an aggregate of $5,000,000.
- New Funding Commitment: The new partner, Zhejiang Haichang Biotechnology Co., Ltd. ("Haichang"), agreed to fund all research and development activities through a Phase IIa clinical trial up to an aggregate amount of $10,000,000.
- Revenue Sharing: For downstream licensing of the new nano-liposomal product, Rexahn will receive 30% of revenues from licensees in mainland China, Hong Kong, Macau, and Taiwan, and 70% from licensees in the rest of the world.
Material Changes Versus Prior Period
The company executed a material change in its commercial strategy for RX-0201:
- Termination of Prior Agreement: Ended the 2003 Research Collaboration Agreement with Rexgene Biotech (successor NEXT BT), which granted exclusive rights for RX-0201 in Asia.
- New Strategic Partnership: Entered the "Haichang Agreement" to develop a nano-liposomal formulation of RX-0201 specifically for HCC in China.
- Portfolio Realignment: Rexahn plans to cease internal development of RX-0201 for metastatic renal cell carcinoma and wind down internally funded programs for this candidate to focus resources on advancing RX-3117 and RX-5902 (Supinoxin) through Phase II clinical development.
Outlook, Risks, and Management Commentary
Management's strategy is to leverage Haichang's proprietary QTzome technology to advance RX-0201 for HCC while reducing internal cash burn on that specific program. Key terms and risks include:
- Development Scope: Haichang will conduct pre-clinical and clinical activities through a Phase IIa proof-of-concept trial in China, designed to meet both U.S. and Chinese regulatory requirements.
- Intellectual Property: Rexahn retains ownership of all inventions arising from the collaboration and receives an exclusive, perpetual, worldwide license to Haichang's IP regarding the product.
- Future Commercialization: Upon completion of the Phase IIa trial, Haichang has a right of first negotiation for an exclusive license in China. If not exercised, Haichang must seek sublicensees in China, while Rexahn seeks sublicensees outside China.
- Adjustment Clauses: Revenue sharing ratios are subject to adjustment if Haichang's qualified expenses exceed $10 million, if Rexahn takes over development, or if an exclusive license is negotiated.
Important Facts for Investor Verification
- Verify the exact status of the $5,000,000 cap on payments to NEXT BT and any immediate cash outflows required upon termination.
- Confirm the timeline for Haichang's funding disbursements and the start date of the Phase IIa clinical trial.
- Assess the impact of winding down internal RX-0201 programs on the company's overall cash runway and burn rate.
- Review the specific regulatory requirements for the nano-liposomal formulation in both China and the U.S. as outlined in the new agreement.
- Monitor the progress of the other drug candidates (RX-3117 and RX-5902) which are now the primary focus of internal resources.